PathMaker launches first clinical trial in ALS of a neuromodulation device that can non-invasively suppress overactive spinal motor neurons found in ALS. Read more here: globenewswire.com/news-release/2…

Our Co-Founder and CEO, Nader Yaghoubi, M.D., Ph.D., will be speaking at the next Expert ALS Talk with EverythingALS to present PathMaker's non-invasive motor neuron hyperexcitability suppression platform and its recently launched ALS trial. #ALSExpertTalks #ALS

Our President and CEO, Nader Yaghoubi, M.D., Ph.D., is delighted to be part of this dynamic discussion. Join us for the FACCNE Life Sciences Panorama on October 18: linkedin.com/events/lifesci…

PathMaker’s CEO and Co-Founder, Nader Yaghoubi, MD, PhD, will be showcasing the MyoRegulator device to leading ALS and neuromuscular disease clinicians at PathMaker’s booth at the 2024 MDA Clinical and Scientific Conference being held March 3-6, 2024 in Orlando, FL.

On April 5 2024, PathMaker’s CEO and Co-Founder, Nader Yaghoubi, M.D., Ph.D., presented the company’s work on treating #ALS and spasticity via a non-invasive motor neuron hyperexcitability suppression approach at the 2024 Bioelectronic Medicine Forum. #medtech #neurostimulation

On July 12, 2024, PathMaker’s Co-Founder and CEO, Nader Yaghoubi, M.D., Ph.D., will join the CEO Soak – an ALS Association event that engages community leaders to get soaked for #ALS to raise funds and awareness. To help raise funds for ALS, please visit bit.ly/PMN24.

PathMaker has been awarded $2.16M in funding from the U.S. Department of Defense. The award will fund PathMaker’s second trial in #ALS for its MyoRegulator® device. Read more here. globenewswire.com/news-release/2… #medicaldevice #neurotechnology #neurostimulation

We need more help! Every contribution, no matter the size, brings us closer to our goal and supports the ALS Association's crucial role in the fight against ALS. So let's rally and make a splash for ALS!  Join us by donating today at bit.ly/PMN24.

At the #ALS Nexus meeting July 14-17 in Dallas, PathMaker and collaborators will be presenting two posters on their recent pre-clinical and clinical studies in ALS. Co-Founder and CEO, Nader Yaghoubi, M.D., Ph.D., will be showcasing the MyoRegulator device at PathMaker’s booth.

We are pleased to announce IRB approval for our DoD-funded CALM study in ALS, which is our second clinical trial in ALS for our MyoRegulator device and is being conducted at Beth Israel Deaconess Medical Center (BIDMC) in Boston. globenewswire.com/news-release/2…

PathMaker's Co-Founder and CEO, Nader Yaghoubi, M.D., Ph.D., will be presenting at the BIO CEO conference, being held in New York City, February 10-11, to discuss the company's breakthrough approach to treating ALS using non-invasive neuromodulation.

We are delighted to welcome Pritesh Shah, Pharm.D., former Chief Commercial Officer at Novocure, to PathMaker Neurosystems’ Board of Directors! Read more here: globenewswire.com/news-release/2… #medtech #medicaldevice #neurostimulation #neuromodulation #amytrophiclateralsclerosis

We are pleased to announce the issuance of three new patents covering the application of our company’s proprietary technology in the treatment of ALS. Read more here: globenewswire.com/news-release/2… #medtech #medicaldevice #neurostimulation #neuromodulation #amytrophiclateralsclerosis

PathMaker’s Co-Founder and CEO, Nader Yaghoubi, M.D., Ph.D., will be speaking at the 2025 MDA Clinical and Scientific Conference next week in Dallas, TX, where he has been invited to be on a panel on “Neural Regeneration”. Join us in Dallas: mdaconference.org #NeuroTech

PathMaker’s Co-Founder and CEO, Nader Yaghoubi, M.D., Ph.D., will be speaking at the 2025 European Neurotech Leaders Forum taking place in Leuven on June 3-4. He will be discussing his company’s non-invasive approach to treating ALS through the restoration of neural pathways.

🚀 PathMaker Neurosystems is expanding to Rhode Island with RILSH funding! We are advancing our non-invasive ALS treatment and will be hiring. Proud to join RI's thriving Life Sciences ecosystem! globenewswire.com/news-release/2…

PathMaker Neurosystems’ non-invasive Multi-Site DCS technology shows tremendous potential in ALS treatment, as demonstrated by extended survival in a mouse model in Frontiers in Neurology. Read more: globenewswire.com/news-release/2… #ALS #Neuromodulation

Joining leaders at #ALSNexus 2025 in Dallas next week to dive into the latest ALS research, treatments & clinical progress! Excited to connect w/ leaders fighting for a cure. 💪Join the effort: event.alsnexus.org/event/beb97dac… #EndALS

PathMaker's Co-Founder and CEO, Nader Yaghoubi, M.D., Ph.D., will be attending NEALS, a leading ALS conference being held October 8-10. PathMaker's clinical collaborators from BIDMC will be presenting a poster on their US Dept. of Defense-funded CALM trial.